3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
9
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Non-small Cell Lung Cancer Metastatic
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Melanoma
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Exanthema
1
Endometrial Neoplasms
1
Disease Progression
1
Diarrhea
1
Chondrosarcoma
1
Carcinoma, Squamous Cell
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Advanced Breast Cancer
1
Interventions
Surveys and Questionnaires
7
Standard of Care
5
Sirolimus
5
Bevacizumab
5
temsirolimus
4
Interviews as Topic
4
Paclitaxel
3
olaparib
2
Vorinostat
2
Olanzapine
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Dasatinib
2
Cetuximab
2
zaleplon
1
vistusertib
1
tilsotolimod
1
pazopanib
1
olanzapine-fluoxetine combination
1
nimotuzumab
1
liposomal doxorubicin
1
capivasertib
1
apatinib
1
Videotape Recording
1
Vemurafenib
1
Valproic Acid
1
Trastuzumab
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Cancer
×
capivasertib
×
Clear all
NCT02338622
2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1
Completed
60 enrolled